Linagliptin Sandoz
DPP-4 Inhibitor for Type 2 Diabetes Mellitus
Quick Facts about Linagliptin Sandoz
Key Takeaways about Linagliptin Sandoz
- Glucose-dependent action: Linagliptin works by enhancing insulin secretion only when blood sugar is elevated, which significantly reduces the risk of hypoglycaemia when used alone
- No renal dose adjustment needed: Unlike most DPP-4 inhibitors, linagliptin is primarily eliminated via the enterohepatic system, making it suitable for patients at any stage of chronic kidney disease
- Once-daily convenience: A single 5 mg tablet taken at the same time each day, with or without food, provides 24-hour blood sugar support
- Well-tolerated profile: Side effects are generally mild; the most commonly reported include nasopharyngitis and cough, with low risk of weight gain
- Flexible combination therapy: Can be combined with metformin, sulfonylureas, thiazolidinediones, or insulin for enhanced glycaemic control
What Is Linagliptin Sandoz and What Is It Used For?
Linagliptin Sandoz is a prescription medicine containing the active substance linagliptin, a DPP-4 inhibitor (gliptin) used to lower blood sugar levels in adults with type 2 diabetes mellitus. It works by increasing the levels of incretin hormones that stimulate insulin release after meals, and it can be used alone or in combination with other diabetes treatments.
Type 2 diabetes mellitus is a chronic metabolic disorder characterised by insulin resistance and progressive beta-cell dysfunction, leading to persistently elevated blood glucose levels (hyperglycaemia). Over time, uncontrolled hyperglycaemia increases the risk of serious complications including cardiovascular disease, nephropathy, retinopathy, and neuropathy. Effective glycaemic management is therefore a cornerstone of diabetes care, with the goal of reducing HbA1c to individualised targets while minimising side effects.
Linagliptin belongs to the class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, sometimes called gliptins. These medications target the incretin system, a hormonal pathway that plays a critical role in post-meal glucose regulation. After eating, the gut releases incretin hormones — primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) — which stimulate insulin secretion from pancreatic beta cells and suppress glucagon release from alpha cells, both in a glucose-dependent manner.
The enzyme DPP-4 rapidly degrades GLP-1 and GIP, giving them a half-life of only 1–2 minutes. By inhibiting DPP-4, linagliptin extends the activity of these incretin hormones, enhancing their beneficial effects on blood sugar control. Because this mechanism is glucose-dependent, the risk of hypoglycaemia is inherently low when linagliptin is used as monotherapy or in combination with metformin.
Linagliptin Sandoz is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control in the following settings:
- Monotherapy: When diet and exercise alone are insufficient and metformin is not appropriate due to intolerance or contraindications (e.g. renal impairment)
- Dual combination therapy: Added to metformin, a sulfonylurea, a thiazolidinedione, or insulin when these agents alone do not achieve adequate glycaemic control
- Triple combination therapy: Added to metformin plus a sulfonylurea, or metformin plus insulin, when dual therapy is insufficient
Linagliptin Sandoz is not suitable for treating type 1 diabetes mellitus or diabetic ketoacidosis. It should always be used as an adjunct to diet and exercise, not as a substitute for lifestyle modifications. If you have type 1 diabetes, your doctor will prescribe insulin-based therapy instead.
How does linagliptin differ from other DPP-4 inhibitors?
One of the most clinically significant advantages of linagliptin over other DPP-4 inhibitors (such as sitagliptin, saxagliptin, or vildagliptin) is its unique pharmacokinetic profile. While most gliptins are predominantly excreted through the kidneys and require dose adjustments in patients with renal impairment, linagliptin is primarily eliminated via the enterohepatic system (biliary excretion). Approximately 80% of the drug is excreted unchanged in the faeces, with less than 5% eliminated renally.
This means that linagliptin can be prescribed at the same dose (5 mg once daily) regardless of kidney function, including in patients with severe chronic kidney disease (CKD) or those undergoing haemodialysis. This characteristic makes linagliptin a particularly valuable option for the large proportion of type 2 diabetes patients who also have impaired renal function, a common comorbidity affecting approximately 40% of this population.
Additionally, the CARMELINA and CAROLINA cardiovascular outcome trials demonstrated that linagliptin has a neutral effect on cardiovascular risk and does not increase the risk of heart failure hospitalisation, providing reassurance about its long-term cardiovascular safety profile.
What Should You Know Before Taking Linagliptin Sandoz?
Before starting Linagliptin Sandoz, inform your doctor about all medical conditions, especially a history of pancreatitis, heart failure, or allergic reactions to DPP-4 inhibitors. Do not use this medicine if you are allergic to linagliptin or any of its ingredients. Special caution is needed when combining with insulin or sulfonylureas due to increased hypoglycaemia risk.
Contraindications
You must not take Linagliptin Sandoz if you have a known hypersensitivity (allergy) to linagliptin or to any of the excipients in the formulation. Allergic reactions to DPP-4 inhibitors can include anaphylaxis, angioedema, and exfoliative skin conditions. If you have previously experienced a serious allergic reaction to another gliptin, discuss this with your doctor before starting treatment.
Linagliptin is not indicated for type 1 diabetes mellitus and should not be used for the treatment of diabetic ketoacidosis (DKA). These conditions require insulin therapy, and substituting a DPP-4 inhibitor would be ineffective and potentially dangerous.
Warnings and Precautions
Several important precautions should be considered before and during treatment with linagliptin:
- Pancreatitis: Cases of acute pancreatitis, including fatal cases, have been reported in patients taking DPP-4 inhibitors, although a causal relationship has not been definitively established. Patients should be informed of the characteristic symptoms of acute pancreatitis: persistent, severe abdominal pain that may radiate to the back, often accompanied by nausea and vomiting. If pancreatitis is suspected, linagliptin should be discontinued immediately and not restarted.
- Bullous pemphigoid: Rare cases of bullous pemphigoid, a blistering skin condition, have been reported with DPP-4 inhibitor use. If bullous pemphigoid is suspected, the medicine should be discontinued.
- Hypoglycaemia risk with insulin or sulfonylureas: When linagliptin is used in combination with insulin or a sulfonylurea, the risk of hypoglycaemia is increased. Your doctor may need to reduce the dose of insulin or the sulfonylurea to mitigate this risk.
- Heart failure: While the CARMELINA trial did not show an increased risk of heart failure hospitalisation with linagliptin, patients with existing heart failure should be monitored, as experience in this population is limited.
Contact your doctor or seek emergency care if you experience: severe and persistent abdominal pain (possible pancreatitis), signs of a serious allergic reaction such as swelling of the face, lips, tongue or throat, difficulty breathing, or severe skin blistering. Stop taking Linagliptin Sandoz and do not restart until advised by your doctor.
Pregnancy and Breastfeeding
The use of Linagliptin Sandoz is not recommended during pregnancy. There are limited data from the use of linagliptin in pregnant women. Animal studies have not indicated direct or indirect harmful effects with respect to reproductive toxicity, but as a precautionary measure, linagliptin should be avoided during pregnancy. Women of childbearing potential should use effective contraception during treatment.
It is not known whether linagliptin is excreted in human breast milk. Animal studies have shown excretion of linagliptin in milk. A decision must be made whether to discontinue breastfeeding or to discontinue linagliptin therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
If you are pregnant, think you may be pregnant, or are planning to have a baby, consult your doctor before taking this medicine. Your doctor will help you transition to a safer alternative, typically insulin, which is the preferred treatment for diabetes during pregnancy.
How Does Linagliptin Sandoz Interact with Other Drugs?
Linagliptin has a relatively low potential for clinically significant drug interactions. The most important interaction is with strong P-glycoprotein/CYP3A4 inducers such as rifampicin, which can reduce linagliptin's effectiveness. Concurrent use with insulin or sulfonylureas increases the risk of low blood sugar, requiring dose adjustments of those medications.
Linagliptin is a substrate of the P-glycoprotein (P-gp) transporter and is partially metabolised by cytochrome P450 enzyme CYP3A4. However, it does not significantly inhibit or induce these systems, meaning it is unlikely to affect the metabolism of other drugs. The pharmacokinetic interactions of linagliptin have been extensively studied, and the following interactions are clinically relevant:
| Interacting Drug | Effect | Severity | Recommendation |
|---|---|---|---|
| Rifampicin | Reduces linagliptin exposure by approximately 40% via CYP3A4/P-gp induction | Major | Combination not recommended; alternative antidiabetic or anti-TB therapy may be needed |
| Ritonavir | Strong CYP3A4/P-gp inhibitor that may increase linagliptin levels | Moderate | Monitor blood glucose; dose adjustment of linagliptin is generally not required |
| Insulin | Pharmacodynamic interaction: increased risk of hypoglycaemia | Major | Consider reducing insulin dose when initiating linagliptin; monitor blood glucose closely |
| Sulfonylureas (e.g. glimepiride, glibenclamide) | Pharmacodynamic interaction: increased risk of hypoglycaemia | Major | Consider reducing sulfonylurea dose; educate patient on hypoglycaemia symptoms |
| Metformin | No clinically significant pharmacokinetic interaction | None | No dose adjustment needed; commonly used in combination |
| Warfarin | No clinically significant pharmacokinetic interaction | None | No dose adjustment needed |
| Digoxin | No clinically significant interaction in pharmacokinetic studies | None | No dose adjustment needed |
Major Interactions
The most clinically significant interaction is with rifampicin, a potent inducer of both CYP3A4 and P-glycoprotein. Co-administration of rifampicin (600 mg daily) with linagliptin reduced linagliptin's area under the curve (AUC) by approximately 40% and its peak plasma concentration (Cmax) by approximately 44%. This reduction may compromise the glucose-lowering efficacy of linagliptin, and the combination is generally not recommended. Patients requiring rifampicin for tuberculosis treatment should discuss alternative antidiabetic options with their physician.
The combination with insulin or sulfonylureas represents a pharmacodynamic rather than pharmacokinetic interaction. Adding linagliptin to these agents increases the overall glucose-lowering effect, which may result in symptomatic hypoglycaemia. To reduce this risk, healthcare providers should consider proactively reducing the dose of insulin or the sulfonylurea when initiating linagliptin therapy, particularly in patients who already have near-target HbA1c levels.
Minor Interactions
Linagliptin has been studied in combination with numerous commonly prescribed medications, and no clinically significant interactions have been observed with metformin, pioglitazone, glyburide, simvastatin, warfarin, digoxin, or oral contraceptives. This favourable interaction profile makes linagliptin particularly suitable for patients on multiple medications, a common scenario in type 2 diabetes management where polypharmacy is the norm.
While strong CYP3A4 inhibitors such as ritonavir may modestly increase linagliptin plasma concentrations, this effect is not considered clinically relevant, and no dose adjustment is recommended. Similarly, other moderate CYP3A4 inducers or inhibitors have not shown meaningful effects on linagliptin pharmacokinetics in clinical studies.
What Is the Correct Dosage of Linagliptin Sandoz?
The recommended dose of Linagliptin Sandoz for all adult patients is 5 mg once daily, taken at the same time each day, with or without food. No dose adjustment is needed for patients with renal or hepatic impairment. Linagliptin is not recommended for children and adolescents under 18 years.
Adults
Standard Adult Dose
The recommended dose is 5 mg once daily. The tablet should be taken at the same time each day, with or without food. Swallow the tablet whole with a glass of water — do not crush, chew, or split it.
When linagliptin is used in combination with a sulfonylurea or insulin, a lower dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycaemia.
The simplicity of linagliptin dosing is one of its clinical advantages. Unlike many other diabetes medications, there is no need for titration from a lower starting dose. All patients begin and remain on the same 5 mg dose regardless of their body weight, age, or kidney function. This simplifies prescribing and improves adherence, particularly in elderly patients or those with complex medication regimens.
| Patient Group | Dose | Adjustment Needed | Notes |
|---|---|---|---|
| Adults (18+) | 5 mg once daily | No | Standard dose for all adult patients |
| Mild renal impairment (eGFR 60–89) | 5 mg once daily | No | No dose adjustment required |
| Moderate renal impairment (eGFR 30–59) | 5 mg once daily | No | No dose adjustment required |
| Severe renal impairment / dialysis (eGFR <30) | 5 mg once daily | No | Unique advantage over other DPP-4 inhibitors |
| Hepatic impairment | 5 mg once daily | No | Based on pharmacokinetic studies; limited data in severe hepatic impairment |
| Elderly (≥65 years) | 5 mg once daily | No | No age-related dose adjustment required; monitor as clinically appropriate |
Children and Adolescents
Linagliptin Sandoz is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of linagliptin have not been established in paediatric patients. Clinical trials in this population have not demonstrated a treatment benefit, and no data are available to support a dosing recommendation. If your child or adolescent has type 2 diabetes, their healthcare provider will recommend alternative treatments, typically metformin and/or insulin.
Elderly Patients
No dose adjustment is required in elderly patients. However, clinical experience in patients aged 80 years and older is more limited. Elderly patients are more likely to have impaired renal function and to be on multiple medications, both of which are well-accommodated by linagliptin's pharmacokinetic profile. Nonetheless, careful clinical monitoring is advisable, particularly regarding hypoglycaemia risk if linagliptin is used in combination with insulin or a sulfonylurea.
Missed Dose
If you forget to take your daily dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose and take the next dose at the usual time. Do not take a double dose to make up for a forgotten tablet. If you are unsure what to do, contact your doctor or pharmacist for advice.
Overdose
During clinical trials, single doses of up to 600 mg of linagliptin (120 times the recommended therapeutic dose) were administered to healthy subjects and were generally well tolerated. There is no experience with doses above 600 mg in humans. In the event of an overdose, employ the usual supportive measures such as removing unabsorbed material from the gastrointestinal tract, clinical monitoring, and instituting clinical therapy as indicated. Linagliptin is not meaningfully removed by haemodialysis or peritoneal dialysis.
To help remember your daily dose, take linagliptin at the same time each day — for example, with breakfast or at bedtime. Setting a daily alarm on your phone can be a simple and effective reminder strategy. Consistency in timing helps maintain steady blood levels of the medication.
What Are the Side Effects of Linagliptin Sandoz?
Linagliptin Sandoz is generally well tolerated. The most commonly reported side effects include nasopharyngitis (common cold symptoms), cough, and hypoglycaemia when used with insulin or sulfonylureas. Serious but rare side effects include pancreatitis and bullous pemphigoid. Most side effects are mild and transient.
Like all medicines, Linagliptin Sandoz can cause side effects, although not everybody experiences them. The overall safety profile of linagliptin has been well characterised through extensive clinical trial programmes involving over 10,000 patients, as well as through post-marketing surveillance. The discontinuation rate due to adverse events in clinical trials was comparable between linagliptin and placebo groups, indicating good overall tolerability.
Side effects are categorised below by frequency, based on data from clinical trials and post-marketing reports:
Common
- Nasopharyngitis (runny nose, sore throat, common cold symptoms)
- Cough
- Hypoglycaemia (low blood sugar) — particularly when used with insulin or sulfonylureas
Uncommon
- Pancreatitis (inflammation of the pancreas)
- Hypersensitivity reactions (urticaria, angioedema, localised skin peeling)
- Nasal congestion
- Constipation
- Mouth ulcers (stomatitis)
Rare
- Bullous pemphigoid (blistering skin condition)
- Rhabdomyolysis (muscle breakdown) — very rare, reported post-marketing
- Severe hypersensitivity including anaphylaxis
Understanding hypoglycaemia risk
One of the important advantages of linagliptin is its glucose-dependent mechanism of action: it stimulates insulin release only when blood glucose is elevated. This means that when used alone (monotherapy) or in combination with metformin, the risk of hypoglycaemia is very low and comparable to placebo. However, when linagliptin is combined with medications that independently cause hypoglycaemia — specifically insulin or sulfonylureas (such as glimepiride or glibenclamide) — the risk of low blood sugar increases significantly.
Symptoms of hypoglycaemia include sweating, trembling, rapid heartbeat, hunger, confusion, dizziness, and in severe cases, loss of consciousness. If you experience these symptoms, consume a fast-acting source of sugar (such as glucose tablets, fruit juice, or sugary drinks) and check your blood glucose level. If hypoglycaemia occurs frequently, consult your doctor about adjusting the dose of your insulin or sulfonylurea.
Pancreatitis: what to watch for
Although pancreatitis is uncommon with linagliptin, it is a potentially serious condition that requires immediate medical attention. The characteristic presentation includes severe, persistent abdominal pain that often radiates to the back and may be accompanied by nausea and vomiting. The pain does not resolve with simple analgesics and typically worsens after eating. If you develop these symptoms, stop taking Linagliptin Sandoz and contact your doctor or seek emergency care immediately.
Patients with a history of pancreatitis may be at increased risk, and the use of linagliptin in these patients should be carefully considered. Risk factors for pancreatitis include gallstones, high triglyceride levels, and heavy alcohol consumption.
Skin reactions
Hypersensitivity reactions including urticaria (hives), angioedema (swelling beneath the skin, particularly around the face and throat), and localised skin exfoliation have been reported. In very rare cases, bullous pemphigoid has occurred, presenting as large fluid-filled blisters on the skin, typically on the trunk and limbs. If you develop any unexplained skin blistering while taking linagliptin, discontinue the medication and seek medical advice promptly.
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed above. You can also report side effects directly to your national pharmacovigilance authority (e.g. the Yellow Card scheme in the UK, MedWatch in the US, or the EMA in Europe). By reporting side effects, you can help provide more information on the safety of this medicine.
How Should You Store Linagliptin Sandoz?
Store Linagliptin Sandoz below 30°C in the original packaging to protect from moisture. Do not use after the expiry date. Keep out of the sight and reach of children. Do not dispose of medicines via wastewater or household waste.
Proper storage of medications is essential to maintain their efficacy and safety throughout their shelf life. Linagliptin Sandoz film-coated tablets should be stored according to the following guidelines:
- Temperature: Store below 30°C (86°F). Do not freeze. Avoid exposure to excessive heat or direct sunlight.
- Moisture protection: Keep the tablets in the original blister packaging until ready to use, as the blister pack provides protection from moisture.
- Expiry date: Do not use this medicine after the expiry date stated on the blister and carton. The expiry date refers to the last day of that month.
- Child safety: Keep this medicine out of the sight and reach of children.
- Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
If you are travelling, you may carry your medication in your hand luggage. Blister packs are preferable to pill boxes for travelling, as they maintain the original packaging protection. If you notice any change in the appearance of the tablets (discolouration, crumbling, unusual odour), do not use them and consult your pharmacist.
What Does Linagliptin Sandoz Contain?
Each Linagliptin Sandoz film-coated tablet contains 5 mg of the active substance linagliptin. The tablets also contain inactive ingredients (excipients) including mannitol, pregelatinised starch, maize starch, copovidone, and magnesium stearate in the core, with a film coating containing hypromellose, titanium dioxide, talc, macrogol, and iron oxide red.
Active ingredient
Each film-coated tablet contains 5 mg linagliptin. Linagliptin is a xanthine-based molecule with the chemical name 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione. It has a molecular weight of 472.54 g/mol and acts as a competitive, reversible DPP-4 inhibitor.
Inactive ingredients (excipients)
The following excipients are present in Linagliptin Sandoz tablets:
- Tablet core: Mannitol (E421), pregelatinised starch, maize starch, copovidone, magnesium stearate
- Film coating: Hypromellose, titanium dioxide (E171), talc, macrogol 6000, iron oxide red (E172)
The film-coated tablets are light pink, round, biconvex, and debossed with a company logo on one side and “D5” on the other side. The tablets are packaged in PVC/PVDC aluminium foil blister packs.
If you have known allergies to any of the above excipients, discuss this with your doctor or pharmacist before taking Linagliptin Sandoz. In particular, patients with hereditary fructose intolerance should note that this product contains mannitol (E421).
Frequently Asked Questions about Linagliptin Sandoz
Linagliptin Sandoz is used to treat type 2 diabetes mellitus in adults. It belongs to a class of medicines called DPP-4 inhibitors (gliptins) that help your body produce more insulin when blood sugar levels are high. It is used alongside diet and exercise, either alone or in combination with other diabetes medications such as metformin, sulfonylureas, thiazolidinediones, or insulin. It is not suitable for type 1 diabetes or diabetic ketoacidosis.
Take one 5 mg tablet once daily at the same time each day, with or without food. Swallow the tablet whole with water — do not crush, chew, or split it. If you miss a dose, take it as soon as you remember unless it is nearly time for your next dose. Never take a double dose. The same 5 mg dose is used regardless of your age, body weight, or kidney function, which makes dosing simple and straightforward.
The most common side effects are nasopharyngitis (cold symptoms, runny nose), cough, and hypoglycaemia (low blood sugar) when taken with insulin or sulfonylureas. Uncommon side effects include pancreatitis and allergic reactions. Most side effects are mild and usually go away on their own. Seek immediate medical attention if you experience severe abdominal pain, difficulty breathing, or skin blistering.
Yes, one of the major advantages of linagliptin is that no dose adjustment is required for patients with impaired kidney function, even in those with severe chronic kidney disease or on dialysis. This is because linagliptin is primarily eliminated through the liver and gut (enterohepatic system), not the kidneys. Less than 5% of the drug is excreted renally, making it unique among DPP-4 inhibitors and particularly suitable for patients with renal comorbidities.
Clinical trials have consistently shown that linagliptin has a weight-neutral effect, meaning it generally does not cause significant weight gain or weight loss. This is an advantage over some other diabetes medications such as sulfonylureas, thiazolidinediones, and insulin, which are associated with weight gain. For patients who are overweight or obese, maintaining a stable weight while improving blood sugar control is a clinically meaningful benefit.
All information is based on international medical guidelines and regulatory documents: EMA Summary of Product Characteristics (SmPC) for linagliptin, FDA Prescribing Information, American Diabetes Association (ADA) Standards of Medical Care in Diabetes 2024, WHO Model List of Essential Medicines, the CARMELINA cardiovascular outcome trial published in JAMA (2019), and the CAROLINA trial published in JAMA (2019). All medical claims have evidence level 1A, the highest quality of evidence.
References
This article is based on the following peer-reviewed sources and international medical guidelines:
- European Medicines Agency (EMA). Summary of Product Characteristics: Linagliptin. Last updated 2024. Available from: EMA product information database.
- U.S. Food and Drug Administration (FDA). Prescribing Information: Tradjenta (linagliptin) tablets. Reference ID: 4896523.
- Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79. doi:10.1001/jama.2018.18269
- Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155-1166. doi:10.1001/jama.2019.13772
- American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes — 2024. Diabetes Care. 2024;47(Supplement_1):S1-S321.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Geneva: World Health Organization; 2023.
- Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18(4):333-347. doi:10.1111/dom.12610
- Schernthaner G, Schernthaner-Reiter MH. Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. Diabetologia. 2018;61(7):1503-1516. doi:10.1007/s00125-018-4547-9
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. NICE guideline NG28. Updated 2022.
- British National Formulary (BNF). Linagliptin. Medicines Complete. Accessed January 2026.
Editorial Team
This article was written and medically reviewed by qualified healthcare professionals following international evidence-based guidelines.
Medical Content
iMedic Medical Editorial Team — Specialists in Endocrinology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board — Independent panel following GRADE evidence framework
Evidence Standards
Level 1A evidence from systematic reviews and meta-analyses of randomised controlled trials
Guidelines Followed
EMA SmPC, FDA PI, ADA Standards 2024, NICE NG28, WHO Essential Medicines List
All content is independently produced with no pharmaceutical company funding or sponsorship. For our full editorial standards, see Editorial Standards.